vhh

VHH antibodies offer stability, specificity, and small size. Biointron showcases their biotech applications from therapeutics to diagnostics.

VHH antibodies trace back to camelids. Biointron explains their discovery, unique properties, and how they advance modern diagnostics and therapeutics.

VHH antibodies, or sdAbs, combine stability and specificity. Biointron explores their camelid origin and their growing role in biotech and medicine.

Antibody drug development has revolutionized biomedicine. Biointron highlights stages from discovery to approval that shape antibody-based therapies.

VHH libraries provide diverse nanobody options. Biointron builds and screens libraries to identify stable, high-affinity binders for diagnostics and therapeutics.

Innovative antibody formats like VHHs, scFvs, and ADCs expand therapeutic options. Biointron explores how these formats drive flexibility and efficacy.

VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~ 15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!

Camelids provide the origin of VHH antibodies. Biointron highlights their unique biology, how VHHs are developed, and their growing use in diagnostics and therapy.

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

VHH antibodies have reshaped biotech. Biointron reviews their discovery, unique advantages, and applications driving innovation in diagnostics and therapeutic development.

VHH antibodies offer stability, small size, and unique binding advantages. Biointron highlights their history, applications, and growing role in research and therapeutics.

Automation transforms antibody workflows. Discover robotic systems and integrated platforms that raise throughput, consistency, and data confidence.

The alpaca advantage: VHH discovery powered by unique immune repertoires. See how Biointron leverages alpaca libraries for robust nanobody identification.

Antibody fragmentation expands versatility. See how Fab, F(ab’)2, and scFv fragments are generated and applied in imaging, therapeutics, and diagnostics.

Explore ethical questions around antibody production in animals, the 3Rs principle, and how recombinant technology reduces animal use while ensuring high-quality science.